Flow cytometric evaluation of Fas expression in relation to response and resistance to anthracyclines in leukemic cells

Cytometry

Volumn 39, Issue 3, 2000, Pages 195-202

  Labroille, Gilles ^a,b   Dumain, Patrice ^a   Lacombe, Francis ^a,b   Belloc, Francis ^a,b  

^a HAUT LÉVÊQUE HOSPITAL   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Fas mediated apoptosis; Flow cytometry; Leukemic cells; Multidrug resistance

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; DAUNORUBICIN; FAS ANTIGEN; GLYCOPROTEIN P; MESSENGER RNA; MONOCLONAL ANTIBODY;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0034161261     PISSN: 01964763     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0320(20000301)39:3<195::AID-CYTO4>3.0.CO;2-A     Document Type: Article

References (31)

1. Dalton WS, Grogan TM, Meltzer PS, Sceper RJ, Durie BGM, Taylor CW, Miller TPJ, Salmon SE. Drug resistance in multiple myeloma and non Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 1989;7:415-424.
2. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug resistance gene in human tumors and tissues. Proc Natl Acad Sci (USA) 1987;84:265-269,
3. Shustik C, Dalton WS, Gros P. P-glycoprotein-mediated multidrug resistance in tumour cells, biochemistry, clinical relevance and modulation. Mol Aspects Med 1995;16:1-78.
4. Scaggiante B, Morassutti C, Tolazzi G, Michelutti A, Baccarani M, Quadrifoglio F. Effect of unmodified triple helix-forming oligodeoxyribonucleotide targeted to human multidrug-resistance gene mdr1 in MDR cancer cells. FEBS Lett 1994;352:380-384.
5. Labroille G, Belloc F, Bilhou-Nabera C, Bonnefille S, Bascans E, Boisseau MR, Bernard P, Lacombe F. Cytometric study of intracellular P-gp expression and reversal of drug resistance. Cytometry 1998;32:86-94.
6. el-Deiry WS. Role of oncogenes in resistance and killing by cancer therapeutic agents. Curr Opin Oncol 1997;9,1:79-87.
7. Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 1994;54:4313-4320.
8. Cole SPC, Bhaardwaj G, Gerlach JH, Mackie, JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG. Overexpression of a transporter gene in a multidrug resistant human lung cancer cell line. Science 1992;258:1650-1654.
9. Vial JP, Belloc F, Dumain P, Besnard, Lacombe F, Boisseau MR, Reiffers J, Bernard P. Study of the apoptosis induced in vitro by antitumoral drugs on leukaemic cells. Leukemia Res 1997;21,2:163-172.
10. Mesner P, Budihardjo I, Kaufmann SH. Chemotherapy-induced apoptosis. Adv Pharmacol 1997;41:461-499.
11. Itoh N, Yonehara S, Ishii A, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis Cell 1991;66:233-243.
12. Krammer PH, Dhein J, Walczak H, Behrmann I, Mariani S, Matiba B, Fath M, Daniel PT, Knipping E, Westendorp MO, Stricker K, Baumler C, Hellbardt S, Germer M, Peter ME, Debatin K-M. The role of APO-1 mediated apoptosis in the immune system. Immunol Rev 1994;142: 175-191.
13. Debatin K-M. Disturbance of the CD95 (APO-1/Fas) system in disorders of lymphohematopoetic cells. Cell Death Diff 1996;3:185.
14. Suda S, Takahashi T, Goldstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a member of the tumor necrosis factor family. Cell 1993;75:1169-1178.
15. Mariani SM, Matiba B, Baumler C, Krammer PH. Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases. Eur J Immunol 1995;25:2303-2307.
16. Podack ER. Functional significance of two cytolytic pathways of cytotoxic T lymphocytes. J Leukocyte Biol 1995;57:548-552.
17. Ju S-T, Panka DJ, Cui H, Ettinger R, El-Khatib M, Sherr DH, Stanger BZ, Marshak-Rothsein A. Fas (CD95)/FasL interactions required for programmed cell death after T-Cell activation. Nature (London) 1995; 373:444-468.
18. Nagata S, Golstein P. The Fas death factor. Science 1995;267:1449-1456.
19. Dhein J, Walczak H, Baumler C, Dehatin KM, Krammer PH. Autocrine T cell suicide mediated by APO-1 (Fas/CD95). Nature (London) 1995; 373:438-441.
20. Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cell Nature Med 1996;2:574-577.
21. Landowski TH, Gleason-Guzman MC, Dalton WS. Selection for drug resistance results in resistance to Fas-mediated apoptosis. Blood 1997; 89,6:1854-1861.
22. Eischen CM, Kottke TJ, Martins LM, Basi GS, Tung JS, Earnshaw WC, Leibson PJ, Kaufmann SH. Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependant on Fas/Fas ligand interactions. Blood 1997;90,3:935-943.
23. Los M, Herr I, Friesen C, Fulda S, Schulze-Osthoff K, Debatin KM. Cross-resistance of CD95-and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). Blood 1997;90,8:3118-3129.
24. Smyth MJ, Krasovskis E, Sutton VR, Johnstone RW. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependant apoptosis. Proc Natl Acad Sci (USA) 1998;95:7024-7029.
25. Johnstone RW, Cretney E, Smyth MJ. P-Glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 1999;93,3:1075-1085.
26. Durrieu F, Belloc F, Lacoste L, Dumain P, Chabrol J, Dachary-Prigent J, Morjani H, Boisseau MR, Reiffers J, Bernard Ph, Lacombe F. Caspase activation is an early event in anthracycline-induced apoptosis and allows detection of apoptotic cells before they are ingested by phagocytes. Exp Cell Res 1998;240:165-175.
27. Friesen C, Fulda S, Debatin K-M. Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells. Leukemia 1997;11:1833-1841.
28. Fulda S, Sieverts H, Friesen C, Herr I, Debatin K-M. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neurablastoma cells. Cancer Res 1997;57:3823-3829.
29. Micheau O, Solary E, Hammann A, Martin F, Dimanche-Boitrel MT. Sensitization of cancer cells treated with cytotoxic drugs to Fas-mediated cytotoxicity. J Natl Cancer Inst 1997;89:783-789.
30. Villunger A, Egle A, Kos M, Hartmann BL, Geley S, Kofler R, Greil R. Drug-induced apoptosis is associated with enhanced Fas (Apo-1/ CD95) ligand expression but occurs independently of Fas (Apo-1/ CD95) signaling in human T-acute lymphatic leukemia cells. Cancer Res 1997;57:3331-3334.
31. Leith CP, Chen IM, Kopeki KJ, Appelbaum FR, Head DR, Godwin JE, Weick JK, Willman CL. Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry : identification of discordant MDR-/Efflux+ and MDR+/Efflux-cases. Blood 1995;86(6): 2329-2342.